Choung, Wonken team published research on Bioorganic & Medicinal Chemistry Letters in 2019 | 16545-68-9

16545-68-9, Cyclopropanol is a cyclopropane in which a hydrogen atom is replaced by a hydroxy group. It is a member of cyclopropanes and an aliphatic alcohol.
Cyclopropanol is a useful research compound. Its molecular formula is C3H6O and its molecular weight is 58.08 g/mol. The purity is usually 95%.
Cyclopropanol is a cyclic organic compound that is synthesized from sodium hydroxide solution, nitrogen atoms, and carbonyl groups. Cyclopropanol has shown inhibitory effects on inflammatory bowel disease in rats. This drug also inhibits the production of hydrogen chloride and hydrochloric acid in the stomach, which can lead to ulcers. Cyclopropanol has been found to be effective against bowel diseases such as Crohn’s disease and ulcerative colitis. This drug has been shown to have strong antioxidant properties, which may be due to its ability to reduce hydroxyl radicals., Quality Control of 16545-68-9

In general, the hydroxyl group makes alcohols polar. 16545-68-9, formula is C3H6O, Because of hydrogen bonding, alcohols tend to have higher boiling points than comparable hydrocarbons and ethers. Quality Control of 16545-68-9

Choung, Wonken;Jung, Hui Jin;Yang, Deokmo;Nam, Eun Hye;Choi, Hyukjoon;Lee, Bo Ram;Park, Min;Jang, Su Min;Lim, Jae Soo;Kim, Woo Sik;Kim, Kyung-Hee;Chin, Jungwook;Jung, Kyungjin;Lee, Geumwoo;Hong, Eunmi;Jang, Tae-ho;Myung, Jayhyuk;Kim, Seong Heon research published 《 Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR》, the research content is summarized as follows. The new class of PPARgamma non-TZD agonist originally derived from the backbone of anti-hypertensive Fimasartan, BR101549, was identified as a potential lead for anti-diabetic drug development. The X-ray crystallog. of BR101549(I) with PPARgamma ligand binding domain (LBD) revealed unique binding characteristics vs. traditional TZD full agonists. The lead candidate, BR101549, has been found activating PPARgamma to the level of Pioglitazone in vitro and indeed has demonstrated its effects on blood glucose control in mouse proof-of-concept evaluation. The attempts to improve its metabolic stability profile through follow-up SAR including deuterium incorporation have been also described.

16545-68-9, Cyclopropanol is a cyclopropane in which a hydrogen atom is replaced by a hydroxy group. It is a member of cyclopropanes and an aliphatic alcohol.
Cyclopropanol is a useful research compound. Its molecular formula is C3H6O and its molecular weight is 58.08 g/mol. The purity is usually 95%.
Cyclopropanol is a cyclic organic compound that is synthesized from sodium hydroxide solution, nitrogen atoms, and carbonyl groups. Cyclopropanol has shown inhibitory effects on inflammatory bowel disease in rats. This drug also inhibits the production of hydrogen chloride and hydrochloric acid in the stomach, which can lead to ulcers. Cyclopropanol has been found to be effective against bowel diseases such as Crohn’s disease and ulcerative colitis. This drug has been shown to have strong antioxidant properties, which may be due to its ability to reduce hydroxyl radicals., Quality Control of 16545-68-9

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts